Vonoprazan Fumarate CAS1260141-27-2
Vonoprazan Fumarate is a next-generation potassium-competitive acid blocker (P-CAB) widely used in the treatment of acid-related gastrointestinal diseases. Compared with traditional proton-pump inhibitors (PPIs), Vonoprazan provides stronger, faster, and longer-lasting acid suppression, making it a highly preferred therapeutic option in modern gastroenterology.
what's Vonoprazan Fumarate CAS 1260141-27-2?
Vonoprazan Fumarate is a potassium-competitive acid blocker (P-CAB) that inhibits gastric H⁺/K⁺-ATPase. Unlike traditional proton pump inhibitors (PPIs), Vonoprazan provides rapid, consistent, and long-lasting gastric acid suppression. It is widely used in pharmaceutical research, preclinical studies, and formulation development for acid-related disorders, including GERD, peptic ulcers, and Helicobacter pylori infection.
This API is supplied with high purity (≥98%), suitable for laboratory research and drug development projects.
Technical Specification
| Item | Description |
|---|---|
| Product Name | Vonoprazan Fumarate |
| Synonyms | TAK-438; Vonoprazan; Potassium-Competitive Acid Blocker |
| CAS No. | 1260141-27-2 |
| Molecular Formula | C21H20N4O6S · C4H4O4 |
| Molecular Weight | approximately 585.6 g/mol |
| Chemical Class | Potassium-Competitive Acid Blocker |
| Pharmacological Category | Acid suppressant / Anti-ulcer agent / Gastrointestinal drug |
| Mechanism of Action | Inhibits gastric H+,K+-ATPase through potassium-competitive binding (non-covalent, reversible) |
| Appearance | White to off-white powder |
| Purity | ≥ 98% – 99% |
| Grade Available | Pharma / Research Grade |
| Solubility | Soluble in DMSO / Methanol; slightly soluble in water |
| pKa | ~ 5.3 (approx.) |
| Storage Conditions | 2-8 °C, keep dry and away from light |
| Shelf Life | 2 years when properly stored |
| Stability | Stable under recommended storage; sensitive to high temperature & moisture |
| HS Code (typical) | 293339 / 300490 |
Key Benefits of Vonoprazan Fumarate
- Fast-acting and long-lasting acid suppression
- Non-enzymatic, reversible mechanism
- Suitable for research in GERD, peptic ulcer, and H. pylori studies
- High-purity API for pharmaceutical development
- Supports formulation and preclinical studies
Applications of Vonoprazan Fumarate
- Gastrointestinal drug development
- GERD and peptic ulcer research
- H. pylori eradication studies
- Comparative studies with PPIs
- Pharmaceutical formulation research
Mechanism of Action
Vonoprazan Fumarate works by directly and reversibly binding to the potassium-binding site of H⁺/K⁺-ATPase in gastric parietal cells:
1. Potassium-Competitive Binding – Blocks the potassium ion site of the H⁺/K⁺-ATPase enzyme.
2. Inhibition of Acid Secretion – Prevents hydrogen ion transport into the stomach, reducing gastric acidity.
3. Rapid Onset – Acid suppression occurs faster than traditional PPIs because of direct competitive binding.
4. Prolonged Effect – Maintains sustained acid suppression regardless of food intake.
Summary: Vonoprazan Fumarate provides controlled gastric acid inhibition through potassium-competitive, reversible enzyme binding, making it suitable for research and pharmaceutical development.
Side Effects
Vonoprazan Fumarate is generally well-tolerated. Observed adverse effects are mostly mild and temporary:
- Headache
- Diarrhea or constipation
- Nausea
- Abdominal discomfort
- Rare mild liver enzyme elevations
Notes: Severe adverse events are uncommon. Safety profile is derived from controlled clinical studies and preclinical research.
Comparison: Vonoprazan Fumarate vs Other Acid Suppressors
| Feature | Vonoprazan Fumarate (P-CAB) | Omeprazole (PPI) | Tegoprazan (P-CAB) |
|---|---|---|---|
| Mechanism | Potassium-competitive H⁺/K⁺-ATPase inhibition | Irreversible proton pump inhibition | Potassium-competitive H⁺/K⁺-ATPase inhibition |
| Onset of Action | Rapid (within hours) | Slower (typically 2–5 days for full effect) | Rapid (within hours) |
| Duration | Long-lasting, sustained acid suppression | Moderate, requires multiple doses | Long-lasting |
| Acid Suppression | Strong and consistent | Moderate, variable with meal timing | Strong and consistent |
| Food Effect | Minimal | Meal-dependent | Minimal |
| Research Applications | GERD, peptic ulcer, H. pylori eradication, comparative P-CAB studies | GERD, peptic ulcer, H. pylori | Similar to Vonoprazan, early clinical studies |
| Safety Profile | Generally well-tolerated; mild GI or headache effects | Generally well-tolerated; rare liver enzyme elevation, GI discomfort | Similar to Vonoprazan; mild side effects reported |
Summary:
Vonoprazan Fumarate provides faster and more consistent acid suppression than traditional PPIs, with a reversible, potassium-competitive mechanism. Compared to other P-CABs, it has extensive clinical data and widespread research applications for GERD, peptic ulcer, and H. pylori studies.
FAQ
Q1: What is Vonoprazan Fumarate used for?
A1: It is used in research to study gastric acid suppression and develop therapies for GERD, peptic ulcers, and H. pylori infections.
Q2: How does Vonoprazan work?
A2: It binds competitively to the potassium site of H⁺/K⁺-ATPase, reducing gastric acid secretion.
Q3: How is it different from PPIs?
A3: Vonoprazan acts faster and provides more consistent acid suppression than traditional proton pump inhibitors.
Q4: Can it be used for pharmaceutical formulation studies?
A4: Yes, the API is suitable for formulation and preclinical research.
Q5: What is the purity of the API?
A5: Purity is ≥98%, verified by HPLC.
Q6: What side effects have been reported?
A6: Mild side effects include headache, nausea, diarrhea, abdominal discomfort, and rare liver enzyme elevation.
Q7: How should Vonoprazan Fumarate be stored?
A7: Store in a cool, dry place at 2–8°C, protected from light.
Q8: Can Vonoprazan be used in comparative studies with PPIs?
A8: Yes, it is often used in research comparing acid suppression efficacy and pharmacokinetics with proton pump inhibitors.
Why Choose Our Vonoprazan Fumarate API?
- High purity ≥98% Vonoprazan Fumarate
- Verified by HPLC and MS for quality consistency
- Suitable for preclinical studies, formulation, and drug development
- Professional COA and analytical documentation available
- Reliable global supply and support for research institutions
certifications
Shipping methods
| Country | Delivery time |
| Untied states | 7-15 DAYS |
| Australia | 7-12 DAYS |
| Germany | 7-12 DAYS |
| Canada | 8-10 DAYS |
| New zealand | 7-10 DAYS |
| Uk | 5-10 DAYS |
| Thailand | 5-8 DAYS |
| Malaysia | 5-8 DAYS |
| Vietnam | 5-8 DAYS |
The delivery time shown above is an estimate. Shipping routes and freight capacity may change from time to time. For the most accurate delivery schedule, please contact us directly.
Payment terms
delivery records
Message us to get your personalized quotation within 24 hours.
-
Whatsapp:+852 6736 4057
-
Telegram:@hinovopept
-
Email:novopept@gmail.com
Hottags：
failure of PPIs, nighttime reflux relief, hiatal hernia support, side-effects vonoprazan, tolerance over time, Vonoprazan Fumarate, vonoprazan, vonoprazan 20mg, vonoprazan fumarate tablets, vonoprazan fumarate uses, vonoprazan fumarate monograph, vonoprazan fumarate solubility, Vonoprazan Fumarate supplier
Hot Tags: vonoprazan fumarate cas1260141-27-2, China vonoprazan fumarate cas1260141-27-2 manufacturers, suppliers, factory
Send Inquiry
